| 000 | 01501 am a22002533u 4500 | ||
|---|---|---|---|
| 042 | _adc | ||
| 100 | 1 | 0 |
_aKhodabukus, Alastair _eauthor _92269 |
| 700 | 1 | 0 |
_aGuyer, Tyler _eauthor _92270 |
| 700 | 1 | 0 |
_aMoore, Axel C. _eauthor _92271 |
| 700 | 1 | 0 |
_aStevens, Molly M. _eauthor |
| 700 | 1 | 0 |
_aGuldberg, Robert E. _eauthor _92273 |
| 700 | 1 | 0 |
_aBursac, Nenad _eauthor _92274 |
| 245 | 0 | 0 | _aTranslating musculoskeletal bioengineering into tissue regeneration therapies |
| 260 | _c2022-10-12. | ||
| 500 | _a/pmc/articles/PMC7614064/ | ||
| 500 | _a/pubmed/36223445 | ||
| 520 | _aMusculoskeletal injuries and disorders are the leading cause of physical disability worldwide and a considerable socioeconomic burden. The lack of effective therapies has driven the development of novel bioengineering approaches that have recently started to gain clinical approvals. In this review, we first discuss the self-repair capacity of the musculoskeletal tissues and describe causes of musculoskeletal dysfunction. We then review the development of novel biomaterial, immunomodulatory, cellular, and gene therapies to treat musculoskeletal disorders. Lastly, we consider the recent regulatory changes and future areas of technological progress that can accelerate translation of these therapies to clinical practice. | ||
| 540 | _a | ||
| 546 | _aen | ||
| 690 | _aArticle | ||
| 655 | 7 |
_aText _2local |
|
| 786 | 0 | _nSci Transl Med | |
| 856 | 4 | 1 |
_uhttp://dx.doi.org/10.1126/scitranslmed.abn9074 _zConnect to this object online. |
| 999 |
_c2062 _d2062 |
||